Crinetics Pharmaceuticals (CRNX) Receivables (2024 - 2026)

Crinetics Pharmaceuticals has reported Receivables for 3 years, with the latest figure at $14.6 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables changed N/A year-over-year to $14.6 million; the trailing twelve-month figure through Mar 2026 stood at $14.6 million (changed N/A YoY), and the FY2025 full-year result was $8.4 million, changed 0.48% from the prior year.
• Receivables for Q1 2026 stood at $14.6 million, up from $8.4 million in the prior quarter.
• The five-year high for Receivables was $14.6 million in Q1 2026, with the low at $8.3 million in Q4 2024.
• Average Receivables over 3 years is $10.4 million, with a median of $8.4 million recorded in 2025.
• Peak annual rise in Receivables reached 0.48% in 2025, while the deepest fall reached 0.48% in 2025.
• Tracing CRNX's Receivables over 3 years: stood at $8.3 million in 2024, then rose by 0.48% to $8.4 million in 2025, then surged by 75.33% to $14.6 million in 2026.
• The last three Receivables figures came in at $14.6 million (Q1 2026), $8.4 million (Q4 2025), and $8.3 million (Q4 2024), per Business Quant data.

Peer Comparison